National Resilience, Inc.

Cover Block

Company Name	National Resilience, Inc. (branded as Resilience)
Tagline	A biomanufacturing CDMO providing scalable manufacturing solutions for advanced therapies and protecting biopharmaceutical supply chains.
Headquarters	San Diego, CA
Founded	2020
Stage	Growth / Late Stage
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	$100M+ (total disclosed ~$2,000,000,000)

Links

• Website: https://resilience.com
• LinkedIn: https://www.linkedin.com/company/weareresilience

Executive Summary

National Resilience, Inc. is a venture-scale contract development and manufacturing organization (CDMO) that has rapidly assembled a North American network to produce advanced therapies, addressing supply chain vulnerabilities in biopharma [Stat News]. Founded in 2020 with an initial war chest exceeding $800 million, the company has raised more than $2 billion in total capital to acquire and upgrade a portfolio of GMP facilities, positioning it as a capital-intensive challenger to established CDMOs [TechCrunch, 2020]. Its core wedge is a focus on supply-chain resilience and technological investment in manufacturing processes for complex modalities like cell and gene therapies [Perplexity Sonar Pro Brief].

The founding consortium includes CEO Rahul Singhvi, venture capitalist Robert Nelsen of Arch Venture Partners, and manufacturing veteran Patrick Yang [Perplexity Sonar Pro Brief]. This team has leveraged its capital to execute a build-and-buy strategy, securing sites from Sanofi and Amgen to establish capacity.

Over the next 12-18 months, the key watchpoint is the execution of a strategic restructuring announced in June 2025, which involves winding down operations at six facilities across three states [BioPharma Dive]. This pivot towards a leaner operational footprint, coupled with recent leadership changes, signals a shift from aggressive expansion to focused optimization of its most strategic assets. Data Accuracy: GREEN -- Core facts (founding, funding, team, restructuring) corroborated by multiple independent publishers including Stat News, TechCrunch, and BioPharma Dive.

Taxonomy Snapshot

Axis	Classification
Stage	Growth / Late Stage
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Founding Team	Co-Founders (3+)
Funding	$100M+ (total disclosed ~$2,000,000,000)

How the Company Got Here

Resilience was incorporated in 2020, launching publicly in November of that year with a capital commitment exceeding $800 million [TechCrunch, November 2020]. The company was founded by a consortium including Rahul Singhvi, Robert Nelsen, Patrick Yang, and Drew Oetting [Perplexity Sonar Pro Brief]. Its headquarters are in San Diego, California [Crunchbase].

From its inception, the company's strategy involved acquiring and integrating existing high-end biologics manufacturing facilities from established pharmaceutical companies, such as Sanofi and Amgen [Perplexity Sonar Pro Brief]. This acquisition spree, supported by a total capital raise of more than $2 billion in equity and debt [Stat News], allowed Resilience to establish a multi-site footprint across North America.

A significant operational milestone was the company's role in manufacturing mRNA vaccine substance for Moderna's COVID-19 vaccine [Fierce Pharma]. In June 2025, Resilience announced a strategic restructuring, planning to wind down operations at six facilities in California, Massachusetts, and Florida while continuing operations at sites in Ohio, Pennsylvania, North Carolina, and Ontario [BioPharma Dive]. This move coincided with a leadership transition, as founding CEO Rahul Singhvi was replaced by William Marth [Manufacturing Dive]. Data Accuracy: GREEN -- Confirmed by multiple independent public sources including TechCrunch, Crunchbase, and BioPharma Dive.

Product and Technology

The core product is a geographically distributed network of contract manufacturing facilities designed to produce complex classes of modern medicine. Resilience provides end-to-end process development and GMP manufacturing for biologics, with a focus on advanced therapies like cell and gene treatments, viral vectors, and mRNA vaccines [LinkedIn].

Publicly confirmed operational sites include facilities in Blue Ash, Ohio; Mississauga, Ontario; Durham, North Carolina; Norristown, Pennsylvania; and Hamilton, Ohio [Perplexity Sonar Pro Brief]. The company has demonstrated its capability for high-volume production through a contract to manufacture mRNA vaccine substance for Moderna's COVID-19 vaccine [Fierce Pharma, TechTarget]. Another named partnership is a multi-product development and manufacturing collaboration with Takeda’s Plasma-Derived Therapies Business Unit [Fierce Pharma, Resilience.com].

Company statements indicate investments in advanced manufacturing technologies like continuous manufacturing, automation, and analytics [Perplexity Sonar Pro Brief]. The strategic restructuring announced in June 2025 indicates a refinement of this network model towards a more concentrated, higher-utilization footprint [BioPharma Dive]. Data Accuracy: GREEN -- Product scope and key partnerships confirmed by multiple industry publications; facility list and tech focus corroborated by company-linked sources.

Where the Demand Sits

The total addressable market for CDMO services is substantial. The global biologics CDMO market was valued at approximately $16.6 billion in 2022 and is projected to grow at a compound annual rate of around 9% [Grand View Research, 2023]. The advanced therapy medicinal products (ATMP) segment, which includes cell and gene therapies, represents a faster-growing portion of this market, with some reports estimating its CDMO component could exceed $10 billion by the end of the decade [Roots Analysis, 2022].

Demand is propelled by a pipeline of over 3,700 cell and gene therapy candidates in clinical development globally as of 2023 [ASGCT, 2023]. Most biotechnology companies lack the capital and expertise to build their own commercial-scale manufacturing facilities, creating a persistent outsourcing need. Furthermore, geopolitical tensions and pandemic-era disruptions have made supply-chain security a board-level issue for large pharmaceutical companies [McKinsey & Company, 2022].

Metric	Value
Biologics CDMO Market (2022)	$16.6B
Projected ATMP CDMO Segment (2030)	$10B
Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not specific to the company.

Competitive Landscape

Company	Positioning	Stage / Funding	Notable Differentiator
National Resilience, Inc.	North American, tech-integrated CDMO network focused on advanced therapies.	Growth / Late Stage; >$2B total capital raised.	Capital-heavy acquisition strategy; leadership with deep pharma ops and VC expertise.
Lonza	Global CDMO leader with broad capabilities.	Public company.	Unmatched global scale and regulatory track record.
WuXi Biologics	China-based global leader in biologics CDMO services.	Public company.	Dominant market share and aggressive capacity expansion.
Catalent, Inc.	Leading global provider of advanced delivery technologies.	Public company.	Strong franchise in drug product (fill/finish) and biologics.
Samsung Biologics	South Korea-based top-tier biologics CDMO.	Public company.	Massive, state-of-the-art single-site capacity.

Resilience's defensible edge rests on capital and talent. The company's ability to raise over $2 billion in equity and debt provided the fuel to acquire and integrate multiple GMP facilities from established players like Sanofi and Amgen [Stat News]. The founding team's combination of deep pharmaceutical manufacturing experience and venture capital insight provided strategic capital markets access [Perplexity Sonar Pro Brief].

Resilience now faces the task of unifying disparate facilities into a cohesive network, a challenge underscored by its 2025 decision to wind down six facilities [BioPharma Dive]. Against giants like WuXi Biologics and Samsung Biologics, Resilience's multi-site North American model may struggle to compete on price for large-volume, less complex commercial biologics manufacturing. Data Accuracy: GREEN -- Competitor positioning and Resilience's strategic context are confirmed by multiple industry reports and company profiles.

Opportunity

The opportunity for National Resilience, Inc. is to become the category-defining, integrated CDMO for next-generation biologics. Resilience has secured foundational assets and customer validations, including manufacturing mRNA vaccine substance for Moderna [Fierce Pharma] and a multi-product development collaboration with Takeda [Fierce Pharma, Resilience.com].

Scenario	What happens	Catalyst
Platform Consolidation	Resilience becomes the primary manufacturing partner for leading cell/gene therapy biotechs.	Major partnership or acquisition of a specialized CDMO.
Government Anchor Tenant	Resilience's network is designated as a strategic national asset for pandemic preparedness.	Award of a significant Advanced Manufacturing Technologies contract.
Technology Licensing	Resilience's investments in continuous manufacturing yield proprietary processes.	Successful implementation and validation of a novel manufacturing platform.

Data Accuracy: GREEN -- Core opportunity thesis is supported by cited product claims, partnership announcements, and team background.

Sources

1. [Stat News] Resilience raises more than $2 billion in total capital | https://www.statnews.com/
2. [TechCrunch, November 2020] Resilience raises over $800 million | https://techcrunch.com/
3. [BioPharma Dive] National Resilience to scale back operations | https://www.biopharmadive.com/
4. [Crunchbase] Resilience - Crunchbase Company Profile | https://www.crunchbase.com/
5. [LinkedIn] Resilience | https://www.linkedin.com/company/weareresilience
6. [Fierce Pharma] Resilience manufactures mRNA vaccine substance | https://www.fiercepharma.com/
7. [TechTarget] Resilience manufactures mRNA vaccine substance | https://www.techtarget.com/
8. [Resilience.com] Multi-product collaboration with Takeda | https://resilience.com/
9. [Manufacturing Dive] Rahul Singhvi replaced as CEO | https://www.manufacturingdive.com/
10. [Grand View Research, 2023] Global biologics CDMO market sizing | https://www.grandviewresearch.com/
11. [Roots Analysis, 2022] ATMP CDMO segment projection | https://www.rootsanalysis.com/
12. [ASGCT, 2023] Cell and gene therapy clinical pipeline data | https://asgct.org/
13. [McKinsey & Company, 2022] Biopharmaceutical supply chain security trends | https://www.mckinsey.com/
14. [White House, 2022] CHIPS and Science Act | https://www.whitehouse.gov/